Form 4: AEON Biopharma Director Shelley Thunen Granted Over 300,000 Restricted Stock Units

AEON Biopharma, Inc. announced that Director Shelley B. Thunen was granted 308,641 Restricted Stock Units (RSUs) as part of her compensation, vesting fully on May 21, 2026.

Summary

• Shelley B. Thunen, a Director of AEON Biopharma, Inc. (AEON), was granted 308,641 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of AEON's Class A Common Stock on the applicable vesting date.
• All 308,641 RSUs are scheduled to vest in full on the one-year anniversary of the grant date, specifically May 21, 2026.
• Following this transaction, Shelley B. Thunen beneficially owns 308,641 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of aligning management interests with shareholders and is a standard compensation practice, indicating stability in governance. There are no negative operational or financial implications from this filing.

Positives

• The grant of 308,641 Restricted Stock Units (RSUs) to Director Shelley B. Thunen aligns her interests with those of shareholders, as the value of her compensation is tied to the future performance of AEON Biopharma's stock.
• This RSU grant serves as a form of long-term incentive compensation, potentially encouraging retention and continued dedication from a key board member.

Negatives

• The RSUs will be settled in cash, which means the director will not directly hold equity shares, potentially limiting the direct shareholder alignment compared to stock grants.

Risks

• The value of the RSU compensation is subject to the future fair market value of AEON Biopharma's Class A Common Stock, meaning the ultimate cash payout could be lower than anticipated if the stock price declines.

Future Outlook

The 308,641 Restricted Stock Units granted to Director Shelley B. Thunen are scheduled to vest fully on May 21, 2026, with settlement in cash based on the fair market value of AEON's Class A Common Stock at that time.

Industry Context

This is a routine compensation filing for a director in a biopharma company. Equity or equity-linked compensation, such as RSUs, is a common practice across industries, including biopharma, to attract and retain talent and align executive and board interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice for executive and board compensation in publicly traded companies, including those in the biopharmaceutical sector.
• The vesting schedule of one year is within typical industry norms for such grants, aiming to provide a long-term incentive.
• Cash settlement of RSUs is also a common alternative to share settlement, often used for tax or administrative reasons, though direct share ownership is sometimes preferred for stronger alignment.

Related Party Transactions

• The grant of Restricted Stock Units (RSUs) to Shelley B. Thunen, a Director of AEON Biopharma, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders if the stock value increases. However, cash settlement means no direct share ownership by the director.
• Employees: No direct impact on general employees is indicated by this filing.
• Management/Board: This grant provides long-term incentive and compensation to a key board member, potentially aiding in retention and motivation.

Next Steps

• The 308,641 Restricted Stock Units (RSUs) granted to Shelley B. Thunen are expected to vest on May 21, 2026.
• Upon vesting, the RSUs will be settled in cash based on the fair market value of AEON Biopharma's Class A Common Stock.

Key Dates

Recommendation

Keywords

AEON Biopharma, AEON, Restricted Stock Units, RSU, Director Compensation, Shelley B. Thunen, SEC Form 4, Insider Transaction, Equity Compensation, Biopharma